|Bid||90.90 x 800|
|Ask||90.98 x 800|
|Day's range||90.05 - 91.70|
|52-week range||62.55 - 97.86|
|Beta (5Y monthly)||0.78|
|PE ratio (TTM)||16.11|
|Earnings date||24 Jul 2020 - 28 Jul 2020|
|Forward dividend & yield||4.72 (5.20%)|
|Ex-dividend date||14 Apr 2020|
|1y target est||97.00|
AbbVie (ABBV) files applications to the FDA and the EMA seeking approval for a new indication of Rinvoq, active psoriatic arthritis. The drug is already marketed to treat rheumatoid arthritis.
FDA approves Lilly's (LLY) Cyramza as a combination regimen for metastatic EGFR-mutated non-small cell lung cancer. Cyramza is now approved for six indications to treat four different types of cancers.
AbbVie (ABBV) closed at $91.04 in the latest trading session, marking a +0.37% move from the prior day.
Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...
The FDA approves AbbVie's (ABBV) Oriahnn oral capsule for checking heavy menstrual bleeding related to uterine fibroids in pre-menopausal women. It will be sold in US markets by June-end.
Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
There are plenty of reasons for investors to like big pharma stocks. They're usually resilient during economic downturns. Many of them have solid growth prospects. And nearly all of them pay dividends.
Zacks Value Trader Highlights: AbbVie, B&G Foods, H&R Block, Microsoft and Apple
Top Ranked Income Stocks to Buy for May 22nd
With an economic revival in motion despite the unfavorable circumstances so far, value stocks offer the much-needed stability to one's portfolio.
AbbVie (ABBV) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.